Increased Cerebrospinal Fluid F2-Isoprostanes are Associated with Aging and Latent Alzheimer’s Disease as Identified by Biomarkers

被引:0
|
作者
Thomas J. Montine
Elaine R. Peskind
Joseph F. Quinn
Angela M. Wilson
Kathleen S. Montine
Douglas Galasko
机构
[1] University of Washington,Department of Pathology
[2] University of Washington,Department of Psychiatry and Behavioral Sciences
[3] VA Puget Sound Health Care System,Mental Illness Research, Education, and Clinical Center
[4] Oregon Health and Science University and Portland VA Medical Center,Department of Neurology
[5] University of California at San Diego,Department of Neurosciences
来源
NeuroMolecular Medicine | 2011年 / 13卷
关键词
Alzheimer’s disease; Cerebrospinal fluid; Biomarkers; Aβ; Tau; F; -isoprostanes;
D O I
暂无
中图分类号
学科分类号
摘要
Alzheimer’s disease (AD) is a common age-related chronic illness with latent, prodrome, and fully symptomatic dementia stages. Increased free radical injury to regions of brain is one feature of prodrome and dementia stages of AD; however, it also is associated with advancing age. This raises the possibility that age-related free radical injury to brain might be caused in part or in full by latent AD. We quantified free radical injury in the central nervous system with cerebrospinal fluid (CSF) F2-isoprostanes (IsoPs) in 421 clinically normal individuals and observed a significant increase over the adult human lifespan (P < 0.001). Using CSF amyloid (A) β42 and tau, we defined normality using results from 28 clinically normal individuals <50 years old, and then stratified 74 clinically normal subjects ≥60 years into those with CSF that had normal CSF Aβ42 and tau (n = 37); abnormal CSF Aβ42 and tau, the biomarker signature of AD (n = 24); decreased Aβ42 only (n = 4); or increased tau only (n = 9). Increased CSF F2-IsoPs were present in clinically normal subjects with the biomarker signature of AD (P < 0.05) and those subjects with increased CSF tau (P < 0.001). Finally, we analyzed the relationship between age and CSF F2-IsoPs for those clinically normal adults with normal CSF (n = 37) and those with abnormal CSF Aβ42 and/or tau (n = 37); only those with normal CSF demonstrated a significant increase with age (P < 0.01). These results show that CSF F2-IsoPs increased across the human lifespan and that this age-related increase in free radical injury to brain persisted after culling those with laboratory evidence of latent AD.
引用
收藏
页码:37 / 43
页数:6
相关论文
共 50 条
  • [21] Cerebrospinal fluid biomarkers in Alzheimer's disease
    Hugon, Jacques
    Dumurgier, Julien
    Cognat, Emmanuel
    Paquet, Claire
    BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE, 2018, 202 (1-2): : 307 - 318
  • [22] From Cerebrospinal Fluid to Blood: The Third Wave of Fluid Biomarkers for Alzheimer's Disease
    Zetterberg, Henrik
    Blennow, Kaj
    JOURNAL OF ALZHEIMERS DISEASE, 2018, 64 : S271 - S279
  • [23] Systemic Tocopherols and F2-Isoprostanes and the Risk of Alzheimer's Disease and Dementia: A Prospective Population-Based Study
    Sundelofa, Johan
    Kilander, Lena
    Helmersson, Johanna
    Larsson, Anders
    Ronnemaa, Elina
    Degerman-Gunnarsson, Malin
    Sjogren, Per
    Basun, Hans
    Lannfelt, Lars
    Basu, Samar
    JOURNAL OF ALZHEIMERS DISEASE, 2009, 18 (01) : 71 - 78
  • [24] Neuropsychiatric correlates of cerebrospinal fluid biomarkers in Alzheimer's disease
    Skogseth, Ragnhild
    Mulugeta, Ezra
    Ballard, Clive
    Rongve, Arvid
    Nore, Sabine
    Alves, Guido
    Aarsland, Dag
    DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2008, 25 (06) : 559 - 563
  • [25] Cerebrospinal fluid biomarkers for pathological processes in Alzheimer's disease
    Rosen, Christoffer
    Zetterberg, Henrik
    CURRENT OPINION IN PSYCHIATRY, 2013, 26 (03) : 276 - 282
  • [26] Clinical usefulness of cerebrospinal fluid biomarkers in Alzheimer's disease
    Pena-Bautista, Carmen
    Alvarez-Sanchez, Lourdes
    Pascual, Rosa
    Jose Moreno, Maria
    Baquero, Miguel
    Chafer-Pericas, Consuelo
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2023, 53 (03)
  • [27] Cerebrospinal fluid biomarkers of Alzheimer's disease in a cohort of adults with Down syndrome
    Henson, Rachel L.
    Doran, Eric
    Christian, Bradley T.
    Handen, Benjamin L.
    Klunk, William E.
    Lai, Florence
    Lee, Joseph H.
    Rosas, H. Diana
    Schupf, Nicole
    Zaman, Shahid H.
    Lott, Ira T.
    Fagan, Anne M.
    ALZHEIMER'S & DEMENTIA: DIAGNOSIS, ASSESSMENT & DISEASE MONITORING, 2020, 12 (01)
  • [28] Cerebrospinal Fluid Biomarkers of Alzheimer's Disease: Current Evidence and Future Perspectives
    McGrowder, Donovan A.
    Miller, Fabian
    Vaz, Kurt
    Nwokocha, Chukwuemeka
    Wilson-Clarke, Cameil
    Anderson-Cross, Melisa
    Brown, Jabari
    Anderson-Jackson, Lennox
    Williams, Lowen
    Latore, Lyndon
    Thompson, Rory
    Alexander-Lindo, Ruby
    BRAIN SCIENCES, 2021, 11 (02) : 1 - 56
  • [29] Cerebrospinal Fluid Biomarkers in Familial Forms of Alzheimer's Disease and Frontotemporal Dementia
    Rostgaard, Nina
    Waldemar, Gunhild
    Nielsen, Jorgen Erik
    Simonsen, Anja Hviid
    DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2015, 40 (1-2) : 54 - 62
  • [30] F2-Isoprostanes Are Associated With Increased Fracture Risk in Type 2 Diabetes
    Wang, Bowen
    Dhaliwal, Ruban
    Ewing, Susan K.
    Schwartz, Ann V.
    Vashishth, Deepak
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2024,